Selected research
Industry Research
Tachykinin Receptor 1 Antibody Industry Research Report 2026
Market perspective
The global Tachykinin Receptor 1 Antibody market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Tachykinin Receptor 1 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Tachykinin Receptor 1 Antibody market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Tachykinin Receptor 1 Antibody market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Tachykinin Receptor 1 Antibody include Merck, Boster Biological Technology, United States Biological, Santa Cruz Biotechnology, Proteintech, ProSci, NSJ Bioreagents, LSBio and GeneTex, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Tachykinin Receptor 1 Antibody market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Tachykinin Receptor 1 Antibody.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Tachykinin Receptor 1 Antibody Market by Company
Merck
Boster Biological Technology
United States Biological
Santa Cruz Biotechnology
Proteintech
ProSci
NSJ Bioreagents
LSBio
GeneTex
FineTest
Everest Biotech
Cusabio
Atlas Antibodies
Advanced Targeting Solutions
Tachykinin Receptor 1 Antibody Segment by Type
Polyclonal
Monoclonal
Tachykinin Receptor 1 Antibody Segment by Application
Western Blot
Flow Cytometry
Immunocytochemistry
Immunofluorescence
Others
Tachykinin Receptor 1 Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tachykinin Receptor 1 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tachykinin Receptor 1 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tachykinin Receptor 1 Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Tachykinin Receptor 1 Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Polyclonal
- Monoclonal
Applications
- Western Blot
- Flow Cytometry
- Immunocytochemistry
- Immunofluorescence
- Others
Companies covered
- Merck
- Boster Biological Technology
- United States Biological
- Santa Cruz Biotechnology
- Proteintech
- ProSci
- NSJ Bioreagents
- LSBio
- GeneTex
- FineTest
- Everest Biotech
- Cusabio
- Atlas Antibodies
- Advanced Targeting Solutions
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Tachykinin Receptor 1 Antibody by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Polyclonal
- 2.2.3 Monoclonal
- 2.3 Tachykinin Receptor 1 Antibody by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Western Blot
- 2.3.3 Flow Cytometry
- 2.3.4 Immunocytochemistry
- 2.3.5 Immunofluorescence
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Tachykinin Receptor 1 Antibody Breakdown Data by Type
- 3.1 Global Tachykinin Receptor 1 Antibody Historic Market Size by Type (2021-2026)
- 3.2 Global Tachykinin Receptor 1 Antibody Forecasted Market Size by Type (2027-2032)
4 Tachykinin Receptor 1 Antibody Breakdown Data by Application
- 4.1 Global Tachykinin Receptor 1 Antibody Historic Market Size by Application (2021-2026)
- 4.2 Global Tachykinin Receptor 1 Antibody Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Tachykinin Receptor 1 Antibody Market Perspective (2021-2032)
- 5.2 Global Tachykinin Receptor 1 Antibody Growth Trends by Region
- 5.2.1 Global Tachykinin Receptor 1 Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Tachykinin Receptor 1 Antibody Historic Market Size by Region (2021-2026)
- 5.2.3 Tachykinin Receptor 1 Antibody Forecasted Market Size by Region (2027-2032)
- 5.3 Tachykinin Receptor 1 Antibody Market Dynamics
- 5.3.1 Tachykinin Receptor 1 Antibody Industry Trends
- 5.3.2 Tachykinin Receptor 1 Antibody Market Drivers
- 5.3.3 Tachykinin Receptor 1 Antibody Market Challenges
- 5.3.4 Tachykinin Receptor 1 Antibody Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Tachykinin Receptor 1 Antibody Players by Revenue
- 6.1.1 Global Top Tachykinin Receptor 1 Antibody Players by Revenue (2021-2026)
- 6.1.2 Global Tachykinin Receptor 1 Antibody Revenue Market Share by Players (2021-2026)
- 6.2 Global Tachykinin Receptor 1 Antibody Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Tachykinin Receptor 1 Antibody Head Office and Area Served
- 6.4 Global Tachykinin Receptor 1 Antibody Players, Product Type & Application
- 6.5 Global Tachykinin Receptor 1 Antibody Manufacturers Established Date
- 6.6 Global Tachykinin Receptor 1 Antibody Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Tachykinin Receptor 1 Antibody Market Size (2021-2032)
- 7.2 North America Tachykinin Receptor 1 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Tachykinin Receptor 1 Antibody Market Size by Country (2021-2026)
- 7.4 North America Tachykinin Receptor 1 Antibody Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Tachykinin Receptor 1 Antibody Market Size (2021-2032)
- 8.2 Europe Tachykinin Receptor 1 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Tachykinin Receptor 1 Antibody Market Size by Country (2021-2026)
- 8.4 Europe Tachykinin Receptor 1 Antibody Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Tachykinin Receptor 1 Antibody Market Size (2021-2032)
- 9.2 Asia-Pacific Tachykinin Receptor 1 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Tachykinin Receptor 1 Antibody Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Tachykinin Receptor 1 Antibody Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Tachykinin Receptor 1 Antibody Market Size (2021-2032)
- 10.2 South America Tachykinin Receptor 1 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Tachykinin Receptor 1 Antibody Market Size by Country (2021-2026)
- 10.4 South America Tachykinin Receptor 1 Antibody Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Tachykinin Receptor 1 Antibody Market Size (2021-2032)
- 11.2 Middle East & Africa Tachykinin Receptor 1 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Tachykinin Receptor 1 Antibody Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Tachykinin Receptor 1 Antibody Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Merck
- 12.1.1 Merck Company Information
- 12.1.2 Merck Business Overview
- 12.1.3 Merck Revenue in Tachykinin Receptor 1 Antibody Business (2021-2026)
- 12.1.4 Merck Tachykinin Receptor 1 Antibody Product Portfolio
- 12.1.5 Merck Recent Developments
- 12.2 Boster Biological Technology
- 12.2.1 Boster Biological Technology Company Information
- 12.2.2 Boster Biological Technology Business Overview
- 12.2.3 Boster Biological Technology Revenue in Tachykinin Receptor 1 Antibody Business (2021-2026)
- 12.2.4 Boster Biological Technology Tachykinin Receptor 1 Antibody Product Portfolio
- 12.2.5 Boster Biological Technology Recent Developments
- 12.3 United States Biological
- 12.3.1 United States Biological Company Information
- 12.3.2 United States Biological Business Overview
- 12.3.3 United States Biological Revenue in Tachykinin Receptor 1 Antibody Business (2021-2026)
- 12.3.4 United States Biological Tachykinin Receptor 1 Antibody Product Portfolio
- 12.3.5 United States Biological Recent Developments
- 12.4 Santa Cruz Biotechnology
- 12.4.1 Santa Cruz Biotechnology Company Information
- 12.4.2 Santa Cruz Biotechnology Business Overview
- 12.4.3 Santa Cruz Biotechnology Revenue in Tachykinin Receptor 1 Antibody Business (2021-2026)
- 12.4.4 Santa Cruz Biotechnology Tachykinin Receptor 1 Antibody Product Portfolio
- 12.4.5 Santa Cruz Biotechnology Recent Developments
- 12.5 Proteintech
- 12.5.1 Proteintech Company Information
- 12.5.2 Proteintech Business Overview
- 12.5.3 Proteintech Revenue in Tachykinin Receptor 1 Antibody Business (2021-2026)
- 12.5.4 Proteintech Tachykinin Receptor 1 Antibody Product Portfolio
- 12.5.5 Proteintech Recent Developments
- 12.6 ProSci
- 12.6.1 ProSci Company Information
- 12.6.2 ProSci Business Overview
- 12.6.3 ProSci Revenue in Tachykinin Receptor 1 Antibody Business (2021-2026)
- 12.6.4 ProSci Tachykinin Receptor 1 Antibody Product Portfolio
- 12.6.5 ProSci Recent Developments
- 12.7 NSJ Bioreagents
- 12.7.1 NSJ Bioreagents Company Information
- 12.7.2 NSJ Bioreagents Business Overview
- 12.7.3 NSJ Bioreagents Revenue in Tachykinin Receptor 1 Antibody Business (2021-2026)
- 12.7.4 NSJ Bioreagents Tachykinin Receptor 1 Antibody Product Portfolio
- 12.7.5 NSJ Bioreagents Recent Developments
- 12.8 LSBio
- 12.8.1 LSBio Company Information
- 12.8.2 LSBio Business Overview
- 12.8.3 LSBio Revenue in Tachykinin Receptor 1 Antibody Business (2021-2026)
- 12.8.4 LSBio Tachykinin Receptor 1 Antibody Product Portfolio
- 12.8.5 LSBio Recent Developments
- 12.9 GeneTex
- 12.9.1 GeneTex Company Information
- 12.9.2 GeneTex Business Overview
- 12.9.3 GeneTex Revenue in Tachykinin Receptor 1 Antibody Business (2021-2026)
- 12.9.4 GeneTex Tachykinin Receptor 1 Antibody Product Portfolio
- 12.9.5 GeneTex Recent Developments
- 12.10 FineTest
- 12.10.1 FineTest Company Information
- 12.10.2 FineTest Business Overview
- 12.10.3 FineTest Revenue in Tachykinin Receptor 1 Antibody Business (2021-2026)
- 12.10.4 FineTest Tachykinin Receptor 1 Antibody Product Portfolio
- 12.10.5 FineTest Recent Developments
- 12.11 Everest Biotech
- 12.11.1 Everest Biotech Company Information
- 12.11.2 Everest Biotech Business Overview
- 12.11.3 Everest Biotech Revenue in Tachykinin Receptor 1 Antibody Business (2021-2026)
- 12.11.4 Everest Biotech Tachykinin Receptor 1 Antibody Product Portfolio
- 12.11.5 Everest Biotech Recent Developments
- 12.12 Cusabio
- 12.12.1 Cusabio Company Information
- 12.12.2 Cusabio Business Overview
- 12.12.3 Cusabio Revenue in Tachykinin Receptor 1 Antibody Business (2021-2026)
- 12.12.4 Cusabio Tachykinin Receptor 1 Antibody Product Portfolio
- 12.12.5 Cusabio Recent Developments
- 12.13 Atlas Antibodies
- 12.13.1 Atlas Antibodies Company Information
- 12.13.2 Atlas Antibodies Business Overview
- 12.13.3 Atlas Antibodies Revenue in Tachykinin Receptor 1 Antibody Business (2021-2026)
- 12.13.4 Atlas Antibodies Tachykinin Receptor 1 Antibody Product Portfolio
- 12.13.5 Atlas Antibodies Recent Developments
- 12.14 Advanced Targeting Solutions
- 12.14.1 Advanced Targeting Solutions Company Information
- 12.14.2 Advanced Targeting Solutions Business Overview
- 12.14.3 Advanced Targeting Solutions Revenue in Tachykinin Receptor 1 Antibody Business (2021-2026)
- 12.14.4 Advanced Targeting Solutions Tachykinin Receptor 1 Antibody Product Portfolio
- 12.14.5 Advanced Targeting Solutions Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst